Biotech entity
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention American Society of Clinical Oncology (ASCO), the most common co-covered peer. SPOT-MAS 10 appears in 1 tracked Biotech story from July 22, 2026.
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention American Society of Clinical Oncology (ASCO), the most common co-covered peer. SPOT-MAS 10 appears in 1 tracked Biotech story from July 22, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SPOT-MAS 10. Shared-story counts are live from our verified record — not editorial picks.
Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia.
SPOT-MAS 10 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
